Pfizer boosts its gene therapy work, bags upstart Bamboo in $645M buyout deal
Bamboo Therapeutics and its nascent gene therapy pipeline is being bought out by Pfizer, just five months after the biotech raised close to $50 million. The pharma giant, already a minority investor in Bamboo, is paying $150 million upfront for the rest of the equity as it sets its sights on becoming a leader in gene therapy development. And there’s another $495 million in milestones on the table for Bamboo’s investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
